TAK-242 is a medication being studied for its potential to help people with severe alcoholic hepatitis and acute-on-chronic liver failure. It works by blocking certain signals in the body that can cause inflammation. Inflammation is a part of the body’s response to injury or illness, but too much inflammation can be harmful, especially in the liver. By reducing this inflammation, TAK-242 may help improve liver function and overall health in patients with these conditions.

Granulocyte Colony-Stimulating Factor (G-CSF) is a therapy that helps the body produce more white blood cells. White blood cells are important for fighting infections and keeping the immune system strong. In this trial, G-CSF is used to support patients with severe liver conditions, as they may have weakened immune systems. By boosting the production of white blood cells, G-CSF aims to help these patients better fight infections and improve their overall health.

Acute-on-Chronic Liver Failure (ACLF) – Acute-on-Chronic Liver Failure is a syndrome that occurs in individuals with chronic liver disease, which may or may not include previously diagnosed cirrhosis. It is characterized by a sudden worsening of liver function, known as acute hepatic decompensation, leading to liver failure. This condition manifests through symptoms such as jaundice and an increased international normalized ratio (INR). ACLF often involves the failure of one or more organs outside the liver, such as the kidneys, brain, blood coagulation system, respiratory system, or cardiovascular system. The severity of ACLF is graded, with Grade 1 involving a risk of mortality, although this description focuses on the progression rather than outcomes. The condition is associated with systemic inflammation and requires careful monitoring of organ function.